+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Postoperative adjuvant chemotherapy using NCS (neocarzinostatin) and 5-FU in the treatment of gastric cancer. First report--A comparison with the 5-year survival rate of patients undergoing combined therapy with MMC and 5-FU

Postoperative adjuvant chemotherapy using NCS (neocarzinostatin) and 5-FU in the treatment of gastric cancer. First report--A comparison with the 5-year survival rate of patients undergoing combined therapy with MMC and 5-FU

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(11): 3064-3070

As a postoperative adjuvant chemotherapy for gastric cancer, we have administered a combination of NCS (Neocarzinostatin) and 5-FU (NF treatment method) and in this paper we have compiled the results obtained in patients who were treated for 5 years in an attempt to compare the 5-year survival rate with that of patients administered a combination of MMC and 5-FU (MF treatment group) and a control group administered no anticancer agents. As the selection of either NF or MF treatment was conducted on an annual basis, this study can be considered an historical controlled study. The results obtained are summarized as follows. On comparing the survival rate of the NF treatment group and the control group, the 5-year survival rate for all patients who underwent curative resection and all patients with histological stage III cancers and the curative resection PS (+) group, as well as the survival period of the non-resected patients, showed a statistically significant difference, indicating that the survival rate was higher in the NF group. On comparing the NF group and the MF group, although no statistically significant difference was observed between then based on a stratified analysis of all resected cases, histological stage differences and n.ps factors, etc., certain values tended to indicate a higher survival rate for the NF group. Moreover, the survival rate of the non-resected patients was more favorable in the NF group. These results confirm that NCS is useful for the treatment of stomach cancer and compares favorably with MMC. The appearance of side-effects was significantly lower in the NF group in comparison with the MF group and the number of patients who had to discontinue therapy was extremely low.

(PDF emailed within 1 workday: $29.90)

Accession: 041020167

Download citation: RISBibTeXText

PMID: 2960267

Related references

Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer. Journal of Cancer Research and Clinical Oncology 143(5): 861-871, 2017

Comparison of 5- and 10-year survival rates in operated gastric cancer patients. Assessment of the 5-year survival rate as a valid indicator of postoperative curability. Langenbecks Archiv für Chirurgie 356(1): 37-42, 1982

Effect of postoperative adjuvant chemotherapy on the survival rate of gastric cancer borrmann type 4. Journal of Kyoto Prefectural University of Medicine 95(1): 27-36, 1986

Ten-year survival of curability B gastric cancer patients treated by tegafur-uracil as postoperative adjuvant chemotherapy in a common public hospital: univariate and multivariate analyses. Fukuoka Igaku Zasshi 103(7): 138-144, 2012

Multihospital randomized study on the adjuvant chemotherapy with mitomycin-C and Futraful for gastric cancer V. Estimation of 5-year survival rate. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 9(11): 2016-2024, 1982

Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database. Langenbeck's Archives of Surgery 401(8): 1179-1190, 2016

No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer. American Journal of Clinical Oncology 34(3): 309-313, 2011

Preoperative administration of antineoplastic agents against gastric cancer. V. Clinical evaluation of combined chemotherapy with neocarzinostatin (NCS) and 5-fluorouracil (combined NF therapy). Nihon Gan Chiryo Gakkai Shi 14(5): 834-841, 1979

Multihospital randomized study on adjuvant chemotherapy with mitomycin C and futraful or UFT for gastric cancer: 7-year survival rate and types of recurrence. Journal of Japan Society for Cancer Therapy 28(8): 1049-1059, 1993

Favourable influence of adjuvant hormone therapy by oxyprogesterone caproate (OPC) and by its combination with tamoxifen on 5-year survival rate of surgical and combined treatment of primary endometrial carcinoma patients. European Journal of Gynaecological Oncology 14(2): 150-153, 1993

Comparison of 5 year and 10 year survival rates in operated gastric cancer patients assessment of the 5 year survival rate as a valid indicator of post operative curability. Langenbecks Archiv fuer Chirurgie 356(1): 37-42, 1982

Postoperative adjuvant chemotherapy and survival outcome of patients with stage Ib gastric cancer A multi-institutional randomized controlled study. Proceedings of the American Association for Cancer Research Annual Meeting 42: 622, 2001

Postoperative adjuvant chemotherapy for gastric cancer, the second report. Analysis of data on 2873 patients followed for five years. Japanese Journal of Surgery 16(3): 175-180, 1986

Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. European Journal of Cancer 32A(2): 235-242, 1996

Long term results of operation alone and postoperative adjuvant chemotherapy in advanced gastric cancer report of 265 patients. Zhonghua Zhongliu Zazhi 9(5): 365-367, 1987